Hyperhomocysteinemia is a risk factor for coronary arteriosclerosis in Japanese patients with type 2 diabetes.

Okada, Eriko; Oida, Koji; Tada, Hideo; Asazuma, K.; Eguchi, Kazuo; Tohda, Gen; Kosaka, Satoru; Takahashi, Sumio; Miyamori, Isamu

doi:10.2337/diacare.22.3.484

Cited by 86 publications

(47 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several studies have demonstrated that Hcy levels are increased in diabetes. Elevated Hcy levels were shown to be a stronger risk factor in diabetics than in non-diabetic patients (1,19,20,21,24,29,30). Plasma Hcy levels were also found to be significantly elevated in our type 2 diabetic patients with atherosclerotic vascular disease when compared with patients without vascular disease.…”

Section: Discussionmentioning

confidence: 49%

“…Hcy levels were found to be elevated in patients with vascular disease and were proposed to contribute to atherosclerosis in patients with coronary artery disease, stroke, and peripheral vascular disease (1,19,20,22,24,28). Hcy-induced vascular pathologies include fragmentation of the internal elastic lamina, disruption of elastic fibers, smooth muscle hyperplasia, and arterial and venous thrombosis (28).…”

Section: Discussionmentioning

confidence: 99%

“…Several studies have demonstrated that plasma Hcy levels are elevated in diabetic patients (18)(19)(20)(21)(22)(23)(24). But the relation of inflammatory activity to Hcy levels is not well established.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Relation of plasma homocysteine levels to atherosclerotic vascular disease and inflammation markers in type 2 diabetic patients

Akalın¹,

Alataş²,

Çolak³

2008

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: Both hyperhomocysteinemia and increased inflammatory activity are shown to be associated with atherosclerosis. The relation of inflammatory activity to homocysteine (Hcy) levels is not well established. In the present study, we aimed to evaluate the relation of plasma Hcy levels to atherosclerotic vascular disease and inflammatory activity in type 2 diabetic patients. Design and methods: In total 90 type 2 diabetic patients were included in the study. Of these patients, 41 had established atherosclerotic vascular disease and 49 had no evidence of atherosclerotic vascular disease. Hcy levels and markers of inflammation, namely C-reactive protein, fibrinogen, erythrocyte sedimentation rate, interleukin-6, and tumor necrosis factor a (TNFa), were measured. Glucose regulation, C-peptide, lipid parameters, and renal functions were also studied. Results: Both Hcy levels and inflammation markers were all significantly elevated in patients with atherosclerotic vascular disease when compared with patients without vascular disease. Reduced renal functions were responsible for the majority of Hcy elevation in patients with vascular disease. Also, renal functions were significantly associated with both Hcy levels and inflammatory markers. There was no correlation between Hcy levels and inflammation markers except for TNFa. Conclusions: Inflammatory activity and Hcy levels are increased in type 2 diabetic patients with atherosclerotic vascular disease. Impairment of renal functions is the key factor that affects both Hcy levels and inflammation markers. Inflammation is not involved in the process by which Hcy leads atherosclerosis in type 2 diabetes.European Journal of Endocrinology 158 47-52

show abstract

Section: Discussionmentioning

confidence: 49%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Relation of plasma homocysteine levels to atherosclerotic vascular disease and inflammation markers in type 2 diabetic patients

Akalın¹,

Alataş²,

Çolak³

2008

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Both clinical and experimental studies have suggested that mild increases in plasma homocysteine may be an independent risk factor for CAD (7,8). A recent study in type 2 diabetes also demonstrated a clear relationship between increased homocysteinemia and increased risk of CAD (9). Hyperhomocysteinemia may be an even stronger risk factor for CAD in subjects with type 2 diabetes than in nondiabetic subjects (10).…”

mentioning

confidence: 96%

Beneficial Effects of a Soy-Based Dietary Supplement on Lipid Levels and Cardiovascular Risk Markers in Type 2 Diabetic Subjects

et al. 2001

View full text Add to dashboard Cite

OBJECTIVE -Consumption of soy protein has recently been shown to improve the blood lipid levels in nondiabetic subjects. The purpose of this study was to evaluate if a dietary supplement of soy protein, isoflavones, and cotyledon fiber (Abalon) affects cardiovascular risk markers, blood glucose, and insulin levels in type 2 diabetic subjects. RESEARCH DESIGN AND METHODS RESULTS -The results are expressed as means ± SD. The percentage mean treatment difference between Abalon and placebo demonstrated significantly lower mean values afterAbalon for LDL cholesterol (10 ± 15%, P Ͻ 0.05), LDL/HDL ratio (12 ± 18%, P Ͻ 0.05), apolipoprotein (apo) B100 (30 ± 38%, P Ͻ 0.01), triglycerides (22 ± 10%, P Ͻ 0.05), and homocysteine (14 ± 21%, P Ͻ 0.01), whereas the total cholesterol value tended to be less significant but still lower (8 ± 15%, P Ͻ 0.08). No change occurred in HDL cholesterol, apo B100/apo A1 ratio, plasminogen activator inhibitor 1, factor VIIc, von Willebrand factor, fibrinogen, lipoprotein(a), glucose, HbA 1c , or 24-h blood pressure. CONCLUSIONS -These results indicate beneficial effects of dietary supplementation withAbalon on cardiovascular risk markers in type 2 diabetic subjects. This improvement is seen even in individuals with near-normal lipid values.

show abstract

“…After removal of unbound proteins by washing of the columns with buffer B (20 mmol/l Tris [pH 7.5], 0.5 mmol/l EDTA, 0.5 mmol/l EGTA, and 10 mmol/l ␤-mercaptoethanol), fractions containing PKC were eluted with buffer C (Tris [pH 7.5], 0.5 mmol/l EDTA, 0.5 mmol/l EGTA, 10 mmol/l ␤-mercaptoethanol, and 0.2 mol/l NaCl). Eluates were analyzed for PKC activity, following the optimum conditions of the assay, by measuring the incorporation of 32 P into the synthetic peptide Ac-myelin basic protein (4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14). The specificity of the assay was determined by subtracting the radioactivity obtained in the presence of the pseudosubstrate inhibitor PKC(19-36) from total radioactivity.…”

mentioning

confidence: 99%

Homocysteine Induces Protein Kinase C Activation and Stimulates c-Fos and Lipoprotein Lipase Expression in Macrophages

Beauchamp

Renier

2002

Diabetes

View full text Add to dashboard Cite

Hyperhomocysteinemia is an independent risk factor for cardiovascular disease in human diabetes. Among the multiple factors that may account for the atherogenicity of homocysteine (Hcys) in patients with diabetes, macrophage (Mo) lipoprotein lipase (LPL) has unique features in that it is increased in human diabetes and acts as a proatherogenic factor in the arterial wall. In the present study, we determined the direct regulatory effect of Hcys on Mo LPL gene expression and secretion.

show abstract

Hyperhomocysteinemia is a risk factor for coronary arteriosclerosis in Japanese patients with type 2 diabetes.

Abstract: There seems to be a clear relationship between hyperhomocysteinemia and an increased risk of coronary arteriosclerosis in Japanese patients with type 2 diabetes.

Cited by 86 publications

References 0 publications

Relation of plasma homocysteine levels to atherosclerotic vascular disease and inflammation markers in type 2 diabetic patients

Relation of plasma homocysteine levels to atherosclerotic vascular disease and inflammation markers in type 2 diabetic patients

Beneficial Effects of a Soy-Based Dietary Supplement on Lipid Levels and Cardiovascular Risk Markers in Type 2 Diabetic Subjects

Homocysteine Induces Protein Kinase C Activation and Stimulates c-Fos and Lipoprotein Lipase Expression in Macrophages

Contact Info

Product

Resources

About